{"url_path":"/sec/bkyi/8-k/2026-07-07/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-07","source_url":"https://www.sec.gov/Archives/edgar/data/1019034/0001437749-26-022880-index.html","accession_number":"0001437749-26-022880","cik":"0001019034","ticker":"BKYI","issuer_name":"BIO KEY INTERNATIONAL INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1019034/0001437749-26-022880-index.html","primary_entity_key":"0001019034","primary_entity_name":"BIO KEY INTERNATIONAL INC"},"word_count":133,"has_tables":true,"body_markdown":"**Item 7.01. Regulation FD Disclosure.**\n\n \n\nOn July 7, 2026, BIO-key International, Inc. (the “Company”) issued a press release regarding the reinstatement of trading of the Company’s common stock on the Nasdaq Capital Market. A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and incorporated herein by reference.\n\n \n\nIn accordance with General Instruction B.2 of Form 8-K, the information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such a filing."}